Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

Watch on YouTube ↗  |  January 12, 2026 at 14:21  |  7:16  |  CNBC
Speakers
Daniel O'Day — Chairman and Chief Executive Officer, Gilead Sciences, Inc.
Becky Quick — Co-Anchor, Squawk Box

Summary

Gilead Sciences CEO and Chairman Daniel O'Day said at the JPMorgan Healthcare Conference that Gilead is entering a new era of growth and impact with its strongest pipeline in nearly 40 years and no major patent expirations in the next decade. He highlighted strong U.S. and global uptake of lenacapavir/Yeztugo for HIV, upcoming oncology catalysts in Trodelvy and CAR-T, and AI's role in speeding trials and manufacturing without replacing primary research.

  • Gilead CEO Daniel O'Day framed the company as entering a new era of growth and impact.
  • O'Day cited up to ten new medicines, a strong financial base, and no major patent expirations in the next ten years.
  • Lenacapavir/Yeztugo has broad U.S. payer coverage and is being made available at no profit in sub-Saharan Africa.
  • O'Day said no lenacapavir resistance has been seen in practice and highlighted its prevention efficacy and future combination potential.
  • Trodelvy may expand into first-line triple negative breast cancer.
  • Gilead's CAR-T therapy for multiple myeloma could become available in the second half of the year.
  • O'Day said AI is already speeding clinical trials and manufacturing but cannot replace scientists in discovering new medicines.
Ideas
Daniel O'Day Chairman and Chief Executive Officer, Gilead Sciences, Inc. 0:36
Gilead's pipeline avoids patent cliff.
Lenacapavir/Yeztugo has seen tremendous U.S. uptake, with every major payer covering it six months after launch, and Gilead is making it available at no profit in sub-Saharan Africa for up to 2 million people while generics ramp. O'Day says no resistance has been seen in practice; lenacapavir alone was almost 100% effective at preventing HIV in more than 9,000 study participants, and it can serve as a backbone for more than seven future combination medicines to provide less frequent dosing.
GILD HIGH
Up Next
15:30
Watch CNBC's full interview with Sen. Mark Warner
CNBC · Jan 12
1:57
Key bank earnings this week: Heres' what to expect
CNBC · Jan 12
7:57
Wired's Steven Levy on DeepSeek's latest AI model, state of AI tech race
CNBC · Jan 12
1:33:11
The OFFICIAL 2026 Crypto Predictions... ft. Polymarket & Delphi
Thread Guy · Jan 12
1:55
What Do Iran's Protests Mean for the World?
Bloomberg Markets · Jan 12

This CNBC video, published January 12, 2026, features Daniel O'Day discussing GILD. 1 trade idea extracted by AI with direction and confidence scoring.

Speakers: Daniel O'Day  · Tickers: GILD